PPD02.02 Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT

In the INSIGHT trial primary analysis (NCT01982955; median follow-up: 21.8 months), tepotinib (a highly selective, once daily [QD] MET inhibitor) + gefitinib improved efficacy versus chemotherapy in patients with EGFR-mutant NSCLC, and resistance to anti-EGFR therapy due to METamp. Here, we report final analyses from INSIGHT (data cut-off: September 3, 2021; median follow-up: 57.5 months). Previously presented at AACR 2022.